A novel in vitro model to screen steroid 5α-reductase inhibitors against benign prostatic hyperplasia

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 20, Issue 4, 1998, Pages 283-287

  Sun, Zu Yue ^a   Tu, Zeng Hong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Drug screening model; Finasteride; Nicotinamide adenine dinucleotide phosphate (NADPH); Spectrophotometry; Steroid 5 reductase inhibitors

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ANIMAL TISSUE; ARTICLE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME MECHANISM; PROSTATE HYPERTROPHY; ULTRAVIOLET SPECTROPHOTOMETRY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; FINASTERIDE; KINETICS; MALE; MICROSOMES, LIVER; NADP; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0345577818     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1998.20.4.485681     Document Type: Article

References (16)

1. Levy, M.A., Brandt, M., Sheedy, K.M., Dinh, J.T., Holt, D.A., Garrison, L.M. et al. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5α-reductase isoform 2. J Steroid Biochem Molec Biol 1994, 48: 197-206.
2. Celler, J., Kirschenbaum, A., Lepor, H., Levine, A.C. Therapeutic controversies: Clinical treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab 1995, 80: 745-56.
3. Boudon, C., Lumbroso, S., Lobaccaro, J.M., Szarras-Czapnik, M., Romer, T.E., Garandeau, P. et al. Molecular study of the 5α-reductase type 2 gene in three European families with 5α-reductase deficiency. J Clin Endocrinol Metab 1995, 80: 2149-53.
4. Horton R. Editorial. Benign prostatic hyperplasia: New insights. J Clin Endocrinol Metab 1992, 74: 504A-C.
5. Andersson, S., Einstein, M., Geissler, W., Patel, S., Wu, L. The molecular biology of steroid 5α-reductase. J Endocrinol Invest 1994, 17(Suppl. 1-3): 12.
6. Tempany, C.M.C., Partin, A.W., Zerhouni, E.A., Zinreich, S.J., Walsh, P.C. The influence of finasteride on the volume of the peripheral and periurethrul zones of the prostate in men with benign prostatic hyperplasia. Prostate 1993, 22: 39-42.
7. Guilbault, G.G. Enzymatic Methods of Analysis. Pergamon Press Ltd.: London 1970, 176-96.
8. Brooks, J.R., Baptista, E.M., Berman, C., Ham, E.A., Hichens, M., Johnston, D.B.R. et al. Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology 1981, 109: 830-6.
9. Prous, J., Castañer, J. Finasteride: Testosterone-5α-reductase inhibitor agent for treatment of BPH. Drugs Fut 1991, 16: 996-1000.
10. Imperato-McGinley, J., Shackleton, C., Orlic, S., Stoner, E. C19 and C21 5β/5α metabolite ratios in subjects treated with the 5α-reductase inhibitor finasteride: Comparison of male pseudohermaphrodites with inherited 5α-reductase deficiency. J Clin Endocrinol Metab 1990, 70: 777-82.
11. Gormley, G.J., Stoner, E., Bruskewttz, R.C., Imperato-McGinley, J., Walsh, P.C., McConnell, J.D. et al. The effect of finasteride in men with benign prostatic hyperplasia. New Engl J Med 1992, 327: 1185-91.
12. Geller, J., Sionit, L. Basic studies and clinical experience with finasteride. J Endocrinol Invest 1994, 17(Suppl. 1-3): 15.
13. Voet, D., Voet, J.G. Biochemistry. John Wiley & Sons: New York 1990, 394-424.
14. Zoppi, S., Lechuga, M., Motta, M. Selective inhibition of the 5α-reductase of the rat epididymis. J Steroid Biochem Molec Biol 1992, 42: 509-14.
15. Salle, E.D., Briatico. G., Giudici, D., Ornati, G., Nesi, M., Panzeri, A. 17β-Acylurea derivatives of 4-azasteroids as inhibitors of testosterone 5α-reductase. J Steroid Biochem Molec Biol 1992, 41: 765-8.
16. Mathews, C.K., Holde, K.E. Biochemistry. Benjamin/Cummings Company, Inc. 1990, 341-5.